Search results for "Antineoplastic agent"

showing 10 items of 1538 documents

Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential

2018

Abstract: Introduction: Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations.Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these. The review also discusses functional and non-functional pNETs and associated inhe…

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical Decision-MakingAntineoplastic AgentsDiseaseNeuroendocrine tumorsBioinformaticsTargeted therapy03 medical and health sciences0302 clinical medicinePredictive Value of TestsFunctional tumorBiomarkers TumormedicineHumansProfiling (information science)Molecular Targeted Therapyneurondocrine tumorPrecision MedicineTherapeutic strategymolecular pathwayHepatologybusiness.industryGene Expression ProfilingGastroenterologyClinical coursehereditary syndrometargeted therapymedicine.diseaseGene Expression Regulation NeoplasticPancreatic NeoplasmsNeuroendocrine Tumors030104 developmental biology030220 oncology & carcinogenesispancreatic tumorFamilial CancerHuman medicinebusinessSignal TransductionExpert review of gastroenterology & hepatology
researchProduct

Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies

2021

The Mediterranean diet (MD) is a combination of foods mainly rich in antioxidants and anti-inflammatory nutrients that have been shown to have many health-enhancing effects. Extra-virgin olive oil (EVOO) is an important component of the MD. The importance of EVOO can be attributed to phenolic compounds, represented by phenolic alcohols, hydroxytyrosol, and tyrosol, and to secoiridoids, which include oleocanthal, oleacein, oleuropein, and ligstroside (along with the aglycone and glycosidic derivatives of the latter two). Each secoiridoid has been studied and characterized, and their effects on human health have been documented by several studies. Secoiridoids have antioxidant, anti-inflammat…

0301 basic medicineSettore MED/09 - Medicina InternaSettore CHIM/10 - Chimica Degli AlimentiMediterranean dietAnti-Inflammatory AgentsReviewDiet MediterraneanAntioxidantsCyclopentane Monoterpeneslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineGlucosidesNeoplasmsIridoidslcsh:QH301-705.5SpectroscopyTraditional medicineGeneral MedicinePhenylethyl AlcoholComputer Science Applications030220 oncology & carcinogenesissecoiridoidsIridoid GlucosidesAntineoplastic AgentsoleocanthalCatalysisInorganic Chemistry03 medical and health sciencesPhenolsOleuropeinOleocanthalmedicineAnimalsHumanscanceroleaceinPhysical and Theoretical ChemistryOlive OilMolecular BiologyPyransAldehydesOrganic ChemistryCancermedicine.diseaseTyrosol030104 developmental biologyAglyconelcsh:Biology (General)lcsh:QD1-999chemistryoleuropeinligstrosideHydroxytyrosolOlive oilInternational Journal of Molecular Sciences
researchProduct

Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization

2015

Imiquimod, a toll-like receptor 7 (TLR7) agonist, is an active pharmaceutical ingredient (API) established for the topical treatment of several dermal cancerous and precancerous skin lesions. Within this work, the immunostimulatory effect of imiquimod is further exploited in a transcutaneous immunization (TCI) approach based on a solid nanoemulsion (SN) formulation. SN contains a combination of imiquimod with the model peptide antigen SIINFEKL as a novel approach to omit needle and syringe and optimize dermal antigen administration. Excipients including sucrose fatty acid esters and the pharmaceutically acceptable oils MCT (middle chain triglycerides), avocado oil, jojoba wax and squalene a…

0301 basic medicineSkin NeoplasmsChemistry PharmaceuticalImmunologyAntineoplastic AgentsImiquimodImmunopotentiatorBiologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health sciencesFreeze-dryingSqualenechemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAdjuvants ImmunologicAntigenIn vivomedicineAnimalsHumansActive ingredientImiquimodChromatographyVaccinationPermeationNanostructuresMice Inbred C57BL030104 developmental biologychemistryLangerhans CellsImmunologyAminoquinolinesImmunizationOilsPrecancerous Conditionsmedicine.drugCellular Immunology
researchProduct

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

2016

CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies modify the interaction between tumor, antigen-presenting cells, and T lymphocytes. With respect to overall survival, clinical studies have shown a major benefit for the anti-CTLA-4 antibody ipilimumab as well as the two anti-PD-1 antibodies nivolumab and pembrolizumab. Following approval of ipilimumab in 2011, the latter two achieved market authorization in the summer of 2015. Immune responses thus…

0301 basic medicineSkin NeoplasmsDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classMedizinAntineoplastic AgentsIpilimumabDermatologyPembrolizumabMonoclonal antibody03 medical and health sciences0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenMelanomabiologybusiness.industryMelanomaAntibodies Monoclonalmedicine.diseaseIpilimumabImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinNivolumabAntibodybusinessmedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells

2017

BACKGROUND: Hepatocellular carcinoma (HCC) has a poor outcome. Most HCCs develop in the context of liver fibrosis and cirrhosis caused by chronic inflammation. Short-term fasting approaches enhance the activity of chemotherapy in preclinical cancer models, other than HCC. Multi-tyrosine kinase inhibitor Sorafenib is the mainstay of treatment in HCC. However, its benefit is frequently short-lived. Whether fasting can alleviate liver fibrosis and whether combining fasting with Sorafenib is beneficial remains unknown. METHODS: 24 hour fasting (2% serum, 0.1% glucose)-induced changes on human hepatic stellate cells (HSC) LX-2 proliferation/viability/cell cycle were assessed by MTT and flow cyto…

0301 basic medicineSorafenibLipopolysaccharidesNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularTime FactorsPhysiologyGlucose uptakeClinical BiochemistryAntineoplastic AgentsLiver Cirrhosis Experimental03 medical and health sciencesFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSorafenib fastingmedicineHepatic Stellate CellsAnimalsHumansneoplasmsCell Proliferationhepatic stellate cellDose-Response Relationship Drugbusiness.industryMedicine (all)Phenylurea CompoundsLiver NeoplasmsCancerCell BiologyFastingHep G2 Cellshepatocellular carcinomaSorafenibmedicine.diseasedigestive system diseasesGene Expression Regulation NeoplasticMice Inbred C57BL030104 developmental biologyEndocrinologyGlucoseHepatocellular carcinomaHepatic stellate cellCancer researchSteatohepatitisbusinessmedicine.drug
researchProduct

Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent

2018

Indicaxanthin is a bioactive and bioavailable betalain pigment extracted from Opuntia ficus indica fruits. Indicaxanthin has pharmacokinetic proprieties, rarely found in other phytochemicals, and it has been demonstrated that it provides a broad-spectrum of pharmaceutical activity, exerting anti-proliferative, anti-inflammatory, and neuromodulator effects. The discovery of the Indicaxanthin physiological targets plays an important role in understanding the biochemical mechanism. In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydr…

0301 basic medicineStatistics and ProbabilityMolecular dynamicPyridinesKainate receptorIndicaxanthinPhytochemical01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyDocking03 medical and health scienceschemistry.chemical_compoundNeoplasmsGlutamate carboxypeptidase IIData MiningHumansEnzyme InhibitorsMM-GBSAPharmacophore modelingBinding SitesGeneral Immunology and MicrobiologyReverse screening010405 organic chemistryAnti-cancerApplied MathematicsPhosphodiesteraseOpuntiaPhosphoserine phosphataseInositol trisphosphateGeneral MedicineAntineoplastic Agents Phytogenic0104 chemical sciencesBetaxanthinsNeoplasm ProteinsNeuromodulatorMolecular Docking SimulationAnti-inflammatory agent030104 developmental biologychemistryBiochemistryDocking (molecular)Modeling and SimulationPharmacophoreGeneral Agricultural and Biological SciencesIndicaxanthin
researchProduct

Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models

2018

Colorectal cancer (CRC) is a highly heterogeneous disease both from a molecular and clinical perspective. Several distinct molecular entities, such as microsatellite instability (MSI), have been defined that make up biologically distinct subgroups with their own clinical course. Recent data indicated that CRC can be best segregated into four groups called consensus molecular subtypes (CMS1-4), each of which has a unique biology and gene expression pattern. In order to develop improved, subtype-specific therapies and to gain insight into the molecular wiring and origin of these subtypes, reliable models are needed. This study was designed to determine the heterogeneity and identify the prese…

0301 basic medicineStromal cellColorectal cancerCellMice NudeAntineoplastic AgentsApoptosisComputational biologyBiologyModels BiologicalArticle03 medical and health sciencesMiceStructure-Activity Relationship0302 clinical medicineIn vivomedicineBiomarkers TumorTumor Cells CulturedAnimalsHumansMolecular BiologyCell ProliferationRegulation of gene expressionDose-Response Relationship DrugGene Expression ProfilingMesenchymal stem cellMicrosatellite instabilityCell DifferentiationNeoplasms ExperimentalCell Biologymedicine.diseaseGene expression profilingGene Expression Regulation NeoplasticOxaliplatin030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisFluorouracilDrug Screening Assays AntitumorColorectal NeoplasmsCell death and differentiation
researchProduct

Cytotoxicity of seven naturally occurring phenolic compounds towards multi-factorial drug-resistant cancer cells

2016

Abstract Introduction In medical oncology, multi-drug resistance (MDR) of cancer cells continues to be a major impediment. We are in quest of novel anti-proliferative agents to overcome drug-resistant tumor cells. Methods In the present study, we investigated the cytotoxicity of 7 naturally occurring phenolic compounds including two isoflavonoids alpinumisoflavone ( 1 ) and laburnetin ( 2 ), one biflavonoid amentoflavone ( 3) , three lignans pycnanthulignene A ( 4 ), pycnanthulignene B ( 5 ), and syringaresinol ( 7 ) and one xanthone, euxanthone ( 6 ) against 9 drug-sensitive and MDR cancer cell lines. The resazurin reduction assay was used to evaluate the cytotoxicity of these compounds, w…

0301 basic medicineSyringaresinolPharmaceutical SciencePharmacologyAmentoflavone03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhenolsIsoflavonoidCell Line TumorNeoplasmsOxazinesDrug DiscoveryHumansCytotoxic T cellCytotoxicityMembrane Potential MitochondrialPharmacologyCell Cycle CheckpointsAlpinumisoflavoneAntineoplastic Agents PhytogenicDrug Resistance MultipleEnzyme Activation030104 developmental biologyXanthenesComplementary and alternative medicinechemistryDrug Resistance NeoplasmApoptosisCaspases030220 oncology & carcinogenesisCancer cellMolecular MedicineReactive Oxygen SpeciesPhytomedicine
researchProduct

Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery

2020

Cathepsin S (CatS) is a secreted cysteine protease that cleaves certain extracellular matrix proteins, regulates antigen presentation in antigen-presenting cells (APC), and promotes M2-type macrophage and dendritic cell polarization. CatS is overexpressed in many solid cancers, and overall, it appears to promote an immune-suppressive and tumor-promoting microenvironment. While most data suggest that CatS inhibition or knockdown promotes anti-cancer immunity, cell-specific inhibition, especially in myeloid cells, appears to be important for therapeutic efficacy. This makes the design of CatS selective inhibitors and their targeting to tumor-associated M2-type macrophages (TAM) and DC an attr…

0301 basic medicineT-Lymphocytesmedicine.medical_treatmentReview02 engineering and technologyCancer immunotherapyNeoplasmsTumor-Associated MacrophagesTumor Microenvironmentcysteine proteaseMolecular Targeted TherapySulfoneslcsh:QH301-705.5Cathepsin SAntigen PresentationDrug Carrierscysteine cathepsintumor-associated macrophage (TAM)ChemistrynanoparticleAzepinesDipeptidesGeneral Medicine021001 nanoscience & nanotechnologyGene Expression Regulation NeoplasticImmunotherapy0210 nano-technologydendritic cellAntigen presentationAntineoplastic AgentsTumor-associated macrophageM2 macrophage03 medical and health sciencesLeucinemedicineHumansProtease InhibitorsAntigen-presenting celltargetingtherapypolarizationTumor microenvironmentT cellDendritic CellsDendritic cellextracellular matrix (ECM)Cathepsinstumor associated macrophage030104 developmental biologylcsh:Biology (General)antigen presenting cellCancer researchNanoparticlesimmune suppressionNanocarriers
researchProduct